BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga
DETROIT, MICHIGAN - April 16, 2025 ( NEWMEDIAWIRE ) - When it comes to treating back pain, particularly chronic lumbar disc disease (cLDD), the industry is falling short. Sure there's surgery, but that's an invasive option that isn't always a success. Pain pills are another option, but that can lead to addiction and a severe change in a patient's quality of life. With more than 16 million Americans suffering from chronic back pain, curing it is a big need that has yet to be met.
It's why the progress BioRestorative Therapies Inc. (NASDAQ: BRTX) is making with BRTX-100, its treatment for chronic back pain, is encouraging. The regenerative medicine company focused on stem cell-based therapies and products was just granted Fast Track designation by the U.S. Food and Drug Administration for BRTX-100, its developmental treatment for cLDD.
Giving It A Speedier In
FDA's Fast Track designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions where there is an unmet medical need. Companies granted Fast Track status are able to have more frequent meetings and written communications with the FDA to discuss the drug's developmental plan, the design of proposed clinical trials and the use of biomarkers. Fast Track designation may also make the company's drug eligible for Priority Review and Accelerated Biologics License Application (BLA) approval.
'We are thrilled that the FDA has granted Fast Track designation, underscoring the potential of BRTX-100 to fill significant unmet medical needs in the treatment of cLDD resulting from ineffective conservative non-surgical approaches or failed surgical interventions, and reflecting the comparatively very positive preliminary Phase 2 clinical data that we have reported to date,' said Lance Alstodt, Chief Executive Officer of BioRestorative. 'Achieving Fast Track designation is an important milestone for BioRestorative, enabling us to work more collaboratively with the FDA as we continue to advance our lead BRTX-100 clinical program toward BLA approval to bring this important and novel stem cell therapy to the millions of cLDD patients waiting for effective pain relief and functional improvement.'
Chronic Back Pain Costs Americans Billions
Without a doubt, cLDD fits the bill for a disease with an unmet need, and many large companies like Pfizer, Abbott Laboratories and Eli Lilly are working on solutions. In the U.S. alone around 80% of adults experience at least one episode of lower back pain in their lifetime. What's more, low back pain is the most common cause of disability among adults 45 to 65 and imposes the highest economic burden on the U.S. healthcare system.
Pain-related conditions cost the U.S. economy a staggering $635 billion annually in medical expenses and lost productivity. Back pain is by far the biggest culprit. Currently, there is no clinical therapy targeting the reversal of disc degeneration or that addresses intervertebral disc cell homeostasis, reports BioRestorative.
It's also a big market opportunity for BioRestorative. The stem cell therapeutics market is projected to reach $54.7 billion by 2033, growing at a CAGR of 12.6% between now and then. It is being driven by demand for regenerative therapies and research grants in this area.
BRTX-100's Promising Results
BRTX-100 is an autologous stem cell product for chronic lower back pain. It uses a patient's stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process.
Safety and efficacy endpoints from an ongoing phase 2 trial for the treatment of cLDD have been encouraging, reported BioRestorative. The company said no serious adverse events (SAEs) were reported in any of the 10 first patients of the prospective, randomized, double-blinded and controlled study. BioRestorative said there was also no dose (40X10 6 cells) limiting toxicity at 26-52 weeks. At 26 weeks 70% of the patients reported a greater than 30% increase in function and a more than 30% decrease in pain. If data continues with this trend, the company is confident it will hit its efficacy endpoints for the phase 2 trial.
Chronic back pain is costly and greatly reduces the quality of life for the more than 16 million Americans who are suffering. BioRestorative wants to change that and believes BRTX-100 holds the answer. With Fast Track designation the company is working closely with the FDA to hopefully get this treatment in the hands of patients sooner, giving millions of people much-needed relief.
Featured photo byGioele FazzerionUnsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
This content was originallypublished on Benzinga.Read further disclosureshere.
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Go ahead: Start celebrating a big quarter for stocks
When 2025 opened, there was plenty of talk of a boffo year for stocks. Tax cuts were coming. Deregulation was coming. Maybe the Federal Reserve would cut interest rates more. So, there was talk the Standard & Poor's 500 would end the year possibly at 7,000 or higher, which would mean a 19% gain on the year. Don't miss the move: Subscribe to TheStreet's free daily newsletter Yes, there might be some tariff increases, but no one - but no one - expected the panic that overtook markets when President Trump unveiled his tariff plans on April 3. The S&P 500 fell as much as 10.4% in the next two days. The president then dialed back the tariff increases, subject to getting trades negotiated by July 9. Related: Veteran analyst offers eye-popping Nvidia, Microsoft stock prediction And, lo and behold, the S&P took off. From an April 7 low, the index has roared back, rising nearly 28% and ending Friday at a record 6,173 after reaching an intraday high of 6,188. 7,000 may seem over-the-top, but . . . For the quarter so far (with one day to go), the S&P 500 is up 10%. It's up 4.4% in June and nearly 5% on the year. The year-to-date return is about the same at the Nasdaq Composite Index; the Nasdaq-100's gain is 7.2% on the year and 17% for the quarter. So, if the S&P 500 hits 10% gains per quarter for the rest of the year, the index would finish 2025 at, maybe, 8,200, a gain of some 40%. Related: Scott Galloway sends strong message on Social Security If you think that's doable, we can think of a bridge you might buy in Brooklyn. In short, we're being a tad silly. Nonetheless, the S&P 500 will end the quarter higher, with the technology sector up 21% and the industrial sector up 12%. Techs are led by Seagate Technology (STX) , up more than 60%, Broadcom (AVGO) , up 61%, and Jabil (JBL) ., up 56% Palantir (PLTR) is up about 45%. Nvidia (NVDA) , Microsoft (MSFT) and Meta Platforms (META) are up 46%, 32% and 28%, respectively. The industrial sector has risen because of gains in a number of defense and related companies, including Boeing (BA) , naval ship builder Huntington Ingalls (HII) , L3Harris Technologies (LHX) and Howmet Aerospace (HWM) . Michael M. Santiago/Getty Images The current environment is bullish and has momentum that won't last forever. In fact, there face risks a-plenty over the next six months, including: The Administration's July 9 deadline for finishing trade negotiations will probably come and go because there are so many deals to negotiate. China and the United States have agreed on terms for exporting rare earth metals to the United States. India and the United States are close to a deal. But the president stopped talks with Canada over a tax dispute. Terms on all agreements, however, will be examined carefully. And a mistake on tariffs can cause investors to panic as they did in April. Related: Nike raises prices and puts the blame purely on tariffs To start, first-quarter earnings were very good with tariffs talked about but having little actual effect. Yet. It depends on how all the negotiations end. And tax changes as big as the Trump Administration is proposing can cause absolutely unforeseen effects that probably won't be seen until later in the year. Still, second-quarter earnings look promising. They unofficially have a soft start on July 10, when Delta Air Lines (DAL) reports results. The parade kicks into higher fear on July 15 when JP Morgan Chase (JPM) and a host of big banks report on July 15. (AMZN) sports the largest percentage of buy ratings: 97% of total ratings, with 3% holds. The Middle East is quiet for now. Israel and Iran are not shooting missiles at one another, and Iran has not blocked the Strait of Hormuz, through which 20% of the world's oil flows. The state of Iran's nuclear materials, however, is not clear. The fear is that the Trump tax bill will increase the U.S. deficit by trillions of dollars over the next few years, and bond yields will soar. (Senate Republicans were able to win a key procedural vote on Saturday.) The 10-year Treasury yield was at 4.87% on Jan. 13 and $4.285% on Friday. Meanwhile, it seems that the Fed will cut its key federal funds rate in September, despite President Trump's complaints that Fed boss Jerome Powell, whose terms ends in 2026, is too slow. The traders have expected two rate cuts all this year, with the first coming in September. Two measures to watch: One is the S&P 500 forward price-earnings ratio which was at 25 on Friday. The 10-year average is 18 to 19. Relative strength indexes are very high. as many as 55 S&P 500 stocks are Friday at RSIs, above 70, a signal they're overvalued. It fell back to 49 at the end of the day. Jabil Circuit, Western Digital (WDC) , Seagate Technology and financial giant Goldman Sachs (GS) all had RSIs are 80 or higher. Bull markets, like we're having, can continue with high RSIs for a while - but not forever. More Tech Stocks: Caution ahead: S&P 500, Nasdaq Composite enter overbought territoryAmazon tries to make AI great again (or maybe for the first time)Google plans major AI shift after Meta's surprising $14 billion moveQuestion of the Week: The S&P 500 Pits the Big Dogs Against the Little Dogs U.S. financial markets and most businesses will be closed on Friday for the July 4 holiday. Earnings are small in number and include only one S&P 500 component: Constellation Brands (STZ) . The shares have struggled all year as alcoholic beverage consumption generally has slumped. Beer stocks have been weak too. Trading volume will peak on Tuesday but will fall rapidly Wednesday and Thursday as Wall Street starts the long weekend early. Related: Legendary fund manager issues stock market prediction as S&P 500 tests all-time highs The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Indianapolis Star
6 hours ago
- Indianapolis Star
When do you get your SSI check for July? See full 2025 schedule
Those who get Supplemental Security Income checks will be getting them on a normal schedule in July. SSI recipients got two checks in May – their May SSI payment issued on May 1 and their June payment on May 30 – because of quirks in the Social Security Administration's calendar. Typically, the payments are issued on the first day of the month, and the May 1 payment went out as expected. But because June 1 fell on a weekend, the payment was sent on May 30, the last business day of May. Payments in July and August will arrive on a more normal schedule, with the July payment issued on Tuesday, July 1, and the August payment on Friday, Aug. 1, according to the SSA calendar. Social Security: 3 reasons I'll be taking benefits long before age 70 SSI beneficiaries will also get two checks in August, October and December. That's because the first date of the following month lands on a weekend or holiday. Here are the dates for SSI payments for the rest of 2025, according to the SSA calendar: There are about 7.4 million Americans who may be disabled or have limited resources getting monthly Supplemental Security Income (SSI) benefit payments. SSI provides benefits for those with limited income or resources, those aged 65 or older, and those who are blind or have a qualifying disability. Children with a qualifying disability can also get SSI, according to the Social Security Administration's website. Adults who earn more than $2,019 from work monthly, typically do not qualify for SSI. About one-third of those SSI recipients also get a benefit from Social Security. Those who may be eligible for SSI can begin the application process online, in person at your local Social Security office, or by calling 1-800-772-1213 (TTY 1-800-325-0778) from 8 a.m. to 7 p.m. local time during the work week. Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @ & @mikesnider & msnider@
8 hours ago
Many forget the damage done by diseases like whooping cough, measles and rubella. Not these families
SIOUX FALLS, S.D. -- In the time before widespread vaccination, death often came early. Devastating infectious diseases ran rampant in America, killing millions of children and leaving others with lifelong health problems. These illnesses were the main reason why nearly one in five children in 1900 never made it to their fifth birthday. Over the next century, vaccines virtually wiped out long-feared scourges like polio and measles and drastically reduced the toll of many others. Today, however, some preventable, contagious diseases are making a comeback as vaccine hesitancy pushes immunization rates down. And well-established vaccines are facing suspicion even from public officials, with Robert F. Kennedy Jr., a longtime anti-vaccine activist, running the federal health department. 'This concern, this hesitancy, these questions about vaccines are a consequence of the great success of the vaccines – because they eliminated the diseases,' said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center. 'If you're not familiar with the disease, you don't respect or even fear it. And therefore you don't value the vaccine.' Anti-vaccine activists even portray the shots as a threat, focusing on the rare risk of side effects while ignoring the far larger risks posed by the diseases themselves — and years of real-world data that experts say proves the vaccines are safe. Some Americans know the reality of these preventable diseases all too well. For them, news of measles outbreaks and rising whooping cough cases brings back terrible memories of lives forever changed – and a longing to spare others from similar pain. With a mother's practiced, guiding hand, 80-year-old Janith Farnham helped steer her 60-year-old daughter's walker through a Sioux Falls art center. They stopped at a painting of a cow wearing a hat. Janith pointed to the hat, then to her daughter Jacque's Minnesota Twins cap. Jacque did the same. 'That's so funny!' Janith said, leaning in close to say the words in sign language too. Jacque was born with congenital rubella syndrome, which can cause a host of issues including hearing impairment, eye problems, heart defects and intellectual disabilities. There was no vaccine against rubella back then, and Janith contracted the viral illness very early in the pregnancy, when she had up to a 90% chance of giving birth to a baby with the syndrome. Janith recalled knowing 'things weren't right' almost immediately. The baby wouldn't respond to sounds or look at anything but lights. She didn't like to be held close. Her tiny heart sounded like it purred – evidence of a problem that required surgery at four months old. Janith did all she could to help Jacque thrive, sending her to the Colorado School for the Deaf and the Blind and using skills she honed as a special education teacher. She and other parents of children with the syndrome shared insights in a support group. Meanwhile, the condition kept taking its toll. As a young adult, Jacque developed diabetes, glaucoma and autistic behaviors. Eventually, arthritis set in. Today, Jacque lives in an adult residential home a short drive from Janith's place. Above her bed is a net overflowing with stuffed animals. On a headboard shelf are photo books Janith created, filled with memories like birthday parties and trips to Mount Rushmore. Jacque's days typically begin with an insulin shot and breakfast before she heads off to a day program. She gets together with her mom four or five days a week. They often hang out at Janith's townhome, where Jacque has another bedroom decorated with her own artwork and quilts Janith sewed for her. Jacque loves playing with Janith's dog, watching sports on television and looking up things on her iPad. Janith marvels at Jacque's sense of humor, gratefulness, curiosity and affectionate nature despite all she's endured. Jacque is generous with kisses and often signs 'double I love yous' to family, friends and new people she meets. 'When you live through so much pain and so much difficulty and so much challenge, sometimes I think: Well, she doesn't know any different,' Janith said. Given what her family has been through, Janith believes younger people are being selfish if they choose not to get their children the MMR shot against measles, mumps and rubella. 'It's more than frustrating. I mean, I get angry inside,' she said. 'I know what can happen, and I just don't want anybody else to go through this.' More than half a century has passed, but Patricia Tobin still vividly recalls getting home from work, opening the car door and hearing her mother scream. Inside the house, her little sister Karen lay unconscious on the bathroom floor. It was 1970, and Karen was 6. She'd contracted measles shortly after Easter. While an early vaccine was available, it wasn't required for school in Miami where they lived. Karen's doctor discussed immunizing the first grader, but their mother didn't share his sense of urgency. 'It's not that she was against it," Tobin said. "She just thought there was time.' Then came a measles outbreak. Karen – who Tobin described as a 'very endearing, sweet child' who would walk around the house singing – quickly became very sick. The afternoon she collapsed in the bathroom, Tobin, then 19, called the ambulance. Karen never regained consciousness. 'She immediately went into a coma and she died of encephalitis,' said Tobin, who stayed at her bedside in the hospital. 'We never did get to speak to her again.' Today, all states require that children get certain vaccines to attend school. But a growing number of people are making use of exemptions allowed for medical, religious or philosophical reasons. Vanderbilt's Schaffner said fading memories of measles outbreaks were exacerbated by a fraudulent, retracted study claiming a link between the MMR shot and autism. The result? Most states are below the 95% vaccination threshold for kindergartners — the level needed to protect communities against measles outbreaks. 'I'm very upset by how cavalier people are being about the measles,' Tobin said. 'I don't think that they realize how destructive this is.' One of Lora Duguay's earliest memories is lying in a hospital isolation ward with her feverish, paralyzed body packed in ice. She was three years old. 'I could only see my parents through a glass window. They were crying and I was screaming my head off,' said Duguay, 68. 'They told my parents I would never walk or move again.' It was 1959 and Duguay, of Clearwater, Florida, had polio. It mostly preyed on children and was one of the most feared diseases in the U.S., experts say, causing some terrified parents to keep children inside and avoid crowds during epidemics. Given polio's visibility, the vaccine against it was widely and enthusiastically welcomed. But the early vaccine that Duguay got was only about 80% to 90% effective. Not enough people were vaccinated or protected yet to stop the virus from spreading. Duguay initially defied her doctors. After intensive treatment and physical therapy, she walked and even ran – albeit with a limp. She got married, raised a son and worked as a medical transcriptionist. But in her early 40s, she noticed she couldn't walk as far as she used to. A doctor confirmed she was in the early stages of post-polio syndrome, a neuromuscular disorder that worsens over time. One morning, she tried to stand up and couldn't move her left leg. After two weeks in a rehab facility, she started painting to stay busy. Eventually, she joined arts organizations and began showing and selling her work. Art "gives me a sense of purpose,' she said. These days, she can't hold up her arms long enough to create big oil paintings at an easel. So she pulls her wheelchair up to an electric desk to paint on smaller surfaces like stones and petrified wood. The disease that changed her life twice is no longer a problem in the U.S. So many children get the vaccine — which is far more effective than earlier versions — that it doesn't just protect individuals but it prevents occasional cases that arrive in the U.S. from spreading further. ' Herd immunity" keeps everyone safe by preventing outbreaks that can sicken the vulnerable. Every night, Katie Van Tornhout rubs a plaster cast of a tiny foot, a vestige of the daughter she lost to whooping cough at just 37 days old. Callie Grace was born on Christmas Eve 2009 after Van Tornhout and her husband tried five years for a baby. She was six weeks early but healthy. 'She loved to have her feet rubbed," said the 40-year-old Lakeville, Indiana mom. "She was this perfect baby.' When Callie turned a month old, she began to cough, prompting a visit to the doctor, who didn't suspect anything serious. By the following night, Callie was doing worse. They went back. In the waiting room, she became blue and limp in Van Tornhout's arms. The medical team whisked her away and beat lightly on her back. She took a deep breath and giggled. Though the giggle was reassuring, the Van Tornhouts went to the ER, where Callie's skin turned blue again. For a while, medical treatment helped. But at one point she started squirming, and medical staff frantically tried to save her. 'Within minutes,' Van Tornhout said, 'she was gone.' Van Tornhout recalled sitting with her husband and their lifeless baby for four hours, "just talking to her, thinking about what could have been.' Callie's viewing was held on her original due date – the same day the Centers for Disease Control and Prevention called to confirm she had pertussis, or whooping cough. She was too young for the Tdap vaccine against it and was exposed to someone who hadn't gotten their booster shot. Today, next to the cast of Callie's foot is an urn with her ashes and a glass curio cabinet filled with mementos like baby shoes. 'My kids to this day will still look up and say, 'Hey Callie, how are you?'' said Van Tornhout, who has four children and a stepson. 'She's part of all of us every day.' Van Tornhout now advocates for childhood immunization through the nonprofit Vaccinate Your Family. She also shares her story with people she meets, like a pregnant customer who came into the restaurant her family ran saying she didn't want to immunize her baby. She later returned with her vaccinated four-month-old. 'It's up to us as adults to protect our children – like, that's what a parent's job is,' Van Tornhout said. 'I watched my daughter die from something that was preventable … You don't want to walk in my shoes.'
